Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12770
Abstract: Resistance of castration‐resistant prostate cancer (CRPC) to enzalutamide and abiraterone involves the expression of constitutively active, truncated androgen receptor (AR) splice variants (AR‐Vs) that lack a C‐terminal ligand‐binding domain (LBD). Both full‐length AR and truncated… read more here.
Keywords: enzalutamide; prostate cancer; domain; epi 7170 ... See more keywords